SCHEMBL10036108

SCHEMBL10036108

CN1C=CC(=C/C=C/C=C2\C(=O)ON=C2c2ccccc2)C=C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 12/20 0.52
▸ MEN1 O00255 10/20 0.52
▸ ALDH1A1 P00352 9/20 0.52
▸ MAPT P10636 8/20 0.52
▸ NPSR1 Q6W5P4 6/20 0.52
▸ MAPK1 P28482 4/20 0.52
▸ LMNA P02545 4/20 0.52
▸ POLB P06746 3/20 0.52
▸ KDM4E B2RXH2 3/20 0.52
▸ PKM P14618 2/20 0.52
▸ PLIN1 O60240 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ PLIN5 Q00G26 1/20 0.52
▸ ABHD5 Q8WTS1 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ GFER P55789 1/20 0.44
▸ RECQL P46063 2/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ GAA P10253 1/20 0.44
▸ USP2 O75604 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10036107 0.92 KMT2A (0.51) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL10036016 0.79 KMT2A (0.48) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL5685863 0.76 MAPT (0.49) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL13760804 0.75 MEN1 (0.40) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL10036025 0.73 KMT2A (0.54) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL9290213 0.72 KMT2A (0.47) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL14138728 0.71 KMT2A (0.67) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL14305631 0.69 KMT2A (0.61) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL4900571 0.69 KMT2A (0.61) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL4900562 0.69 KMT2A (0.61) KMT2AMEN1ALDH1A1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 — — US disclosed
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT SNCA, PSEN1, CDR2 KMT2A 2624/4885MEN1 2218/4885ALDH1A1 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback